{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ocugen, Inc. Hits New 52-Week High at $1.78, Marking Significant Milestone
Ocugen, Inc. has achieved a new 52-week high of USD 1.78, significantly up from its low of USD 0.52. Despite this milestone, the company's one-year performance lags behind the S&P 500. With a market cap of USD 322 million, Ocugen remains in a loss-making position amid industry competition.
Ocugen, Inc. Hits New 52-Week High of $1.69, Marking Significant Milestone
Ocugen, Inc. has achieved a new 52-week high of USD 1.69, significantly up from its low of USD 0.52. Despite this milestone, the company's 1-year performance lags behind the S&P 500. Ocugen, with a market cap of USD 322 million, remains loss-making and does not offer dividends.
Is Ocugen, Inc. technically bullish or bearish?
As of August 1, 2025, Ocugen, Inc. has a mildly bullish technical trend, supported by strong short-term momentum and positive indicators, despite some mixed signals in longer-term metrics, and has outperformed the S&P 500 with a year-to-date return of 73.91%.
Is Ocugen, Inc. overvalued or undervalued?
As of February 9, 2024, Ocugen, Inc. is rated as risky due to significant negative financial ratios indicating overvaluation, despite a strong year-to-date stock performance of 73.91%.
Ocugen, Inc. Hits New 52-Week High of $1.48, Signaling Strong Momentum
Ocugen, Inc. has achieved a new 52-week high of USD 1.48, rebounding from a low of USD 0.52. Despite this recent gain, the company has experienced a one-year decline of 9.68%. With a market cap of USD 322 million, Ocugen remains in a challenging financial position.
Ocugen, Inc. Hits New 52-Week High of $1.32, Marking Significant Milestone
Ocugen, Inc. has achieved a new 52-week high of USD 1.32, contrasting with its low of USD 0.52. Despite this milestone, the company's one-year performance is down 14.84%. With a market cap of USD 322 million, Ocugen remains in a loss-making position amid a competitive industry landscape.
Is Ocugen, Inc. overvalued or undervalued?
As of February 9, 2024, Ocugen, Inc. is rated as "risky" and overvalued due to significant negative financial metrics, including a Price to Book Value of 19.46 and unfavorable EV ratios, despite a year-to-date return of 21.88% and a 26.23% decline over the past year.
Is Ocugen, Inc. technically bullish or bearish?
As of June 6, 2025, Ocugen, Inc. shows a mildly bullish trend primarily due to a bullish weekly MACD and KST, despite mixed signals from moving averages and Dow Theory.
Who are in the management team of Ocugen, Inc.?
As of March 2022, the management team of Ocugen, Inc. is led by Dr. Shankar Musunuri as Chairman and CEO, alongside independent directors Ms. Kirsten Castillo, Dr. Prabhavathi Fernandes, Mr. Uday Kompella, Dr. Ramesh Kumar, and Mr. Manish Potti.
What does Ocugen, Inc. do?
Ocugen, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for eye diseases. As of March 2025, it has a market cap of $318.45 million, with recent net sales of $1 million and a net loss of $15 million.
How big is Ocugen, Inc.?
As of Jun 18, Ocugen, Inc. has a market capitalization of 318.45 million, with net sales of 4.52 million and a net profit of -57.48 million over the latest four quarters. The company reported shareholder's funds of 29.63 million and total assets of 83.34 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
